{
    "Case ID": "013073",
    "Different Crime": [
        {
            "Crime Name": "Patent Infringement Dispute",
            "Crime Type": "Economic_Crimes_or_Fraud-related_Offenses",
            "legal_basis": [
                "Section 6(1) of the Patented Medicines (Notice of Compliance) Regulations",
                "Subsection 27(3) of the Patent Act"
            ],
            "decision_outcome": [
                "The 768 Patent allegations were unjustified",
                "The 546 Patent allegations were justified due to insufficient data"
            ],
            "expert_testimony": [
                "The court analyzed claim construction, expert testimonies, and data sufficiency"
            ],
            "patent_validity": [
                "non-infringement of the 768 Patent",
                "invalidity of the 546 Patent"
            ],
            "technical_details": [
                "context showed it was not limited to racemates",
                "issues arose over averaging results, solubility problems, and reliance on sodium salt data for calcium claims"
            ],
            "applicable_statute": [
                "Section 6(1) of the NOC Regulations"
            ],
            "cause_of_action": [
                "Ranbaxy sought approval for a generic version of Pfizer's atorvastatin calcium"
            ],
            "appeal_outcome": [
                "prohibited issuance of a Notice of Compliance for Ranbaxy's product concerning the 768 Patent",
                "dismissed Pfizer's application regarding the 546 Patent due to insufficiency"
            ]
        }
    ]
}